Syndax Pharmaceuticals, Inc.
HealthcareNASDAQ:SNDX · NASDAQ Global Select
+$0.34 today
Vol 1.05M · Avg 1.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-441.6%
avg -100.8%
ROIC
-66.6%
avg -51.8%
ROA
-53.9%
avg -42.6%
Analysis
ROA is currently the strongest return metric at -53.9% versus its period average of -42.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael A. Metzger | Chief Executive Officer & Director | $1.61M | — | 55 | $139,252.00 | 0.16% |
Nicholas Botwood MBBS | Head of Research & Development and Chief Medical Officer | $876,846.00 | — | 58 | $60,885.00 | 0.07% |
Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer | $852,548.00 | — | 55 | $139,252.00 | 0.16% |
Luke J. Albrecht | Senior Vice President, General Counsel & Secretary | $842,308.00 | — | 47 | $14,000.00 | 0.02% |
Steven Closter | Chief Commercial Officer | $822,878.00 | — | 57 | — | — |
Michael Downes | Co-Founder | — | — | — | $484,843.00 | 0.55% |
Peter Ordentlich | Co-Founder & Chief Scientific Officer | — | — | 57 | $0.00 | <0.01% |
Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board | — | — | 76 | — | — |
Kevin McManus | Chief People Officer | — | — | 57 | — | — |
Sharon Klahre | Vice President of Investor Relations & Communications | — | — | — | — | — |
Richard A. Heyman | Co-Founder | — | — | 69 | $139,252.00 | 0.16% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$5.50M
Net Sentiment
$5.50M
Net selling
Most Active
Metzger Michael A
5 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $5.50M over the last 12 months. That adds up to net selling of $5.50M. Metzger Michael A was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +64.5% (15yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +64.5% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Who manages SNDX?
Syndax Pharmaceuticals, Inc. (SNDX) lists 11 active executives. The top listed executive is Michael Downes, Co-Founder.
Are SNDX insiders buying or selling?
Recent insider activity shows net buying of $46.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.